<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

COLO 205

Description

COLO 205 (Colorectal Cancer CDX Model) 

The COLO 205 colorectal cancer cell line was derived from ascites of a patient with metastatic adenocarcinoma. It is KRAS and BRAF wild-type, offering a distinct profile compared to other colorectal cancer models. COLO 205 has been extensively used in preclinical drug testing. Its genetic stability makes it a reproducible tool in colon cancer studies. 

Key Features: 

  • Derived from metastatic colorectal adenocarcinoma. 
  • KRAS/BRAF wild-type. 
  • Epithelial morphology with glandular growth. 
  • Consistent tumor formation in xenografts. 

Applications: 
COLO 205 is applied in screening therapies for colorectal cancer, especially those targeting KRAS-independent pathways. It supports biomarker validation and mechanistic studies of colon tumor biology. Researchers frequently use it as a comparator to KRAS- or BRAF-mutant lines. Its stable genetics make it suitable for translational research.

Details
Tumor Type
Bowel
Tumor Subtype
Duke's type D, Colorectal Adenocarcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
APC
Mutation: p.T1556NfsTer3
Effect: Frameshift Variant
Impact: Pathogenic
ATM
Mutation: p.R189KfsTer17
Effect: Frameshift Variant
BRAF
Mutation: p.V600E
Effect: Missense Variant
Impact: Pathogenic & Likely Pathogenic & Not Provided
TP53
Mutation: p.Y103LfsTer42
Effect: Frameshift Variant
Mutation: p.Y107Ter
Effect: Frameshift Variant
Lumin Data
RNASeq WES
Expression Data
Growth Curve
View on Lumin